|
KMID : 0370220160600040222
|
|
Yakhak Hoeji
2016 Volume.60 No. 4 p.222 ~ p.225
|
|
|
Clinical Evaluation of Losartan and other ARBs on Uric Acid Lowering in Hypertensive Patients with Gout
|
|
Ye Kyong-Nam
Lim Sung-Cil
|
|
|
Abstract
|
|
|
|
Elevated serum uric acid was a risk factor for the development of cardiovascular disease, particularly in patients with hypertension (HTN). In a recent study, losartan is only ARBs on serum uric acid level reduction. However, the effects of losartan on serum uric acid levels in the patients concomitantly treated with urate lowering agents have not been fully elucidated. The purposes of the present study were to evaluate the clinical effects of losartan compared with other ARBs on serum uric acid level in hypertensive patients concomitantly treated with urate lowering agents. Data were etrospectively retrieved from medical records of patients with the diagnosis of HTN and gout who were treated with antihypertensive agents (ARBs) and urate lowering agents. Serum uric acid were measured at 0, 1st and 2nd OPD f/u after the ARB treatment was started. 59 patients were selected by the research protocol. Of these, 9 took losartan, 16 took olmesartan, 5 took irbesartan, 3 took telmisartan, 8 took valsartan, 5 took candesartan, 2 took fimasartan and 11 not took ARBs. Losartan did not significantly reduced serum uric acid compared with the other ARBs during follow-up (2.37 mg/dl vs. 2.36 mg/dL, p = 0.68). And, this effect was still continued (2.87 mg/dl vs. 2.66 mg/dl, p = 0.58). In conclusion, this study shows that losartan has no effect on reducing serum uric acid levels in hypertensive patients with gout at combination antihypertensive agent and urate lowering agents. Further related studies are needed to confirm these results.
|
|
|
KEYWORD
|
|
|
uric acid, gout, hypertension, ARBs, losartan
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|